Rovira clinic

Question 1

driver mutations to test for in NSCLC

Answer 1

EGFR, ALK, ROS1, BRAF, PDL1

Question 2

durvulumab mechanism

Answer 2

immune checkpoint inhibitor that blocks the interaction of PD-L1 with PD-1 and CD80

Question 3

consolidation chemotherapy

Answer 3

Chemotherapy given once a remission is achieved. The goal of this therapy is to sustain a remission. Consolidation chemotherapy may also be called intensification therapy. Usually refers to AML

Question 4

ara-C generic name

Answer 4

cytarabine

Question 5

hindgut refers to

Answer 5

colon and rectum

Question 6

Ki67 index

Answer 6

Evaluates proliferative rate of NET, which has prognostic value

Question 7

IDAC

Answer 7

intermediate dose cytarabine

Question 8

intention of palliative chemotherapy

Answer 8

symptomatic benefit

Question 9

secondary neoplasm

Answer 9

tumor arising from metastatic spread or as a consequence of radiation or chemotherapy treatment of primary tumor

Question 10

threshold for cobalamin deficiency

Answer 10

400

Question 11

TXA mechanism

Answer 11

inhibits fibrinolysis

Question 12

poor prognostic features of localized CRC (stage II high vs. low risk)

Answer 12

lymphovascular invasion, obstruction, perforation

Question 13

low vs high risk stage III CRC

Answer 13

nodal status (4 or more conferring high risk)

Question 14

xeloda SE’s

Answer 14

palmar-plantar erythrodysesthesia

Question 15

5 FU enzyme issue

Answer 15

Dipyrimidine dehydrogenase activity (leads to severe SE’s)

Question 16

5-FU SE’s

Answer 16

cardiotoxicity (MI, angina, arrythmia, CHF)

Question 17

cetuximab SE’s

Answer 17

infusion reactions, acneiform rash, pulmonary toxicity

Question 18

term for neoplasm arising from treatment

Answer 18

treatment related neoplasm

Question 19

syndrome to know from ATRA treatment + presentation

Answer 19

differentiation syndrome, dyspnea, fever, pulmonary edema or infiltrates, effusions, weight gain, bone pain

Question 20

NCCN recommendation for management of first CR in ALL

Answer 20

allogeneic stem cell transplant

Question 21

management of hairy cell leukemia

Answer 21

Observation. Initiate treatment if systemic symptoms, splenic pain, recurrent infection, hgb<12, platelet count <100, ANC<1

Question 22

first line treatment options for hairy cell leukemia

Answer 22

cladribine

pentostatin

Question 23

Clinical significance of mismatch repair protein deficiency for CRC

Answer 23

no benefit from 5-FU

Question 24

adjuvant management of stage III CRC

Answer 24

FOLFOX (only approved adjuvant chemo)

Question 25

significance of mutant KRAS in CRC

Answer 25

no benefit from cetuximab